Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Panagiotis Kottaridis et al.|Leukemia|2023Cited by 48
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Michael J. Austin et al.|Blood Neoplasia|2024Cited by 36